<DOC>
	<DOCNO>NCT02654132</DOCNO>
	<brief_summary>The purpose study determine add elotuzumab pomalidomide low-dose dexamethasone effective treatment relapse refractory multiple myeloma compare pomalidomide low-dose dexamethasone alone .</brief_summary>
	<brief_title>Trial Pomalidomide Low-dose Dexamethasone With Without Elotuzumab Treat Refractory Relapsed Refractory Multiple Myeloma ( ELOQUENT-3 )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com ≥ 2 prior line therapy must include least 2 consecutive cycle lenalidomide proteosome inhibitor alone combination Documented refractory relapse refractory multiple myeloma Refractory proteosome inhibitor lenalidomide , last treatment Relapsed refractory patient must achieve least partial response previous treatment proteosome inhibitor lenalidomide , , progress within 6 month , refractory last treatment Measurable disease screen Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Active plasma cell leukemia Prior treatment pomalidomide Unable tolerate thromboembolic prophylaxis study Prior autologous stem cell transplant within 12 week Known Human Immunodeficiency Virus ( HIV ) infection active hepatitis A , B , C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>